secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001193125-21-237056
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Q2 loss narrows to $16.9M, cash $207.8M; FDA clinical hold on MGTA-117
------------------------------------------------------------------------------

- Net loss $16.9M in Q2 2021 vs $19.1M in Q2 2020; cash $207.8M sufficient into Q3 2023.
- MGTA-117 IND clinical hold: FDA requires additional bioassay to inform dose escalation; toxicology/manufacturing not at issue.
- Enrollment complete for Phase 2 MGTA-145 + plerixafor in multiple myeloma; final data expected Q4 2021.
- Plans to initiate Phase 2 MGTA-145 trial in sickle cell disease in Q4 2021 with bluebird bio.
- Director Mike Bonney resigned Aug 3; no disagreement; board reduced to 9; Alison Lawton named Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312521237056/0001193125-21-237056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312521237056/d206907d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-237056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer